Xingqi Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xingqi Dong has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
Mi Zhang
Department of Infectious Diseases, Yunnan Provincial Infectious Diseases Hospital, Kunming, China
13 shared publications- Xueshan Xia
Kunming University of Science and Technology
13 shared publications Li Gao
Faculty of Life Science and Technology & Yunnan Province Key Laboratory of Public Health and Biosafety, Kunming University of Science and Technology, Kunming, China
10 shared publications- Yue Feng
Faculty of Life Science and Technology & Yunnan Province Key Laboratory of Public Health and Biosafety, Kunming University of Science and Technology, Kunming, China
10 shared publications Cuixian Yang
Department of Clinical Laboratory, Yunnan Provincial Infectious Diseases Hospital, Kunming, China
4 shared publicationsJianjian Li
Department of Infectious Diseases, Yunnan Provincial Infectious Diseases Hospital, Kunming, China
4 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in BMC Infectious Diseases
A case report of complex co-infection with Talaromyces marneffei and Rhodococcus equi in a patient with AIDS
- 14 September 2026
- Published by Springer Nature in BMC Infectious Diseases
Open AccessA case report of complex co-infection with Talaromyces marneffei and Rhodococcus equi in a patient with AIDS
- Open Access
- 23 June 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Emergence of two novel HIV-1 Circulating Recombinant Forms (CRF190_0708 and CRF191_0708): molecular characterization and clinical insights from a five-year study in Yunnan, China
Background: To characterize HIV-1 molecular epidemiology and identify novel circulating recombinant forms (CRFs) among antiretroviral therapy (ART)-naïve heterosexuals in Yunnan, China, and evaluate their clinical impact. Methods: This study examined 636 HIV-1 pol sequences to analyze genetic diversity, pretreatment drug resistance (PDR), and transmission networks. Near full-length genomes were obtained to identify and characterize novel recombinants, with their evolutionary history inferred by Bayesian analysis. Co-receptor tropism was predicted, and the five-year clinical outcomes (including immune reconstitution and virologic response) of patients infected with the novel CRFs were compared. Results: The most prevalent type identified was CRF08_BC, accounting for 50.16% of cases. The prevalence of drug resistance was 5.97% (38/636), with the K103N mutation being the most common. An analysis of transmission networks revealed that 52.2% (272/521) of clusters were associated with CRF07_BC and CRF08_BC. Two novel second-generation CRFs were identified: CRF190_0708, with an estimated time to the most recent common ancestor (tMRCA) of 1998.9, and CRF191_0708, with a more recent tMRCA ranging from 2009.5 to 2011.6. During the five-year follow-up period, viral rebound was observed in 7 patients in the CRF190_0708 group and in 1 patient in the CRF191_0708 group. Drug-resistance mutations (M184V and K103N) were detected in a subset of rebound cases in the CRF190_0708 group. Conclusions: This study identifies two novel HIV-1 recombinants, CRF190_0708 and CRF191_0708, highlighting ongoing viral evolution in Yunnan. Preliminary findings suggest possible clinical differences, warranting further investigation. Continued molecular surveillance is needed. Trial registration: The clinical study was registered at ClinicalTrials.gov under the identifier NCT03852849. The date of registration was March 22, 2019.
- 23 June 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessEmergence of two novel HIV-1 Circulating Recombinant Forms (CRF190_0708 and CRF191_0708): molecular characterization and clinical insights from a five-year study in Yunnan, China
Background: To characterize HIV-1 molecular epidemiology and identify novel circulating recombinant forms (CRFs) among antiretroviral therapy (ART)-naïve heterosexuals in Yunnan, China, and evaluate their clinical impact. Methods: This study examined 636 HIV-1 pol sequences to analyze genetic diversity, pretreatment drug resistance (PDR), and transmission networks. Near full-length genomes were obtained to identify and characterize novel recombinants, with their evolutionary history inferred by Bayesian analysis. Co-receptor tropism was predicted, and the five-year clinical outcomes (including immune reconstitution and virologic response) of patients infected with the novel CRFs were compared. Results: The most prevalent type identified was CRF08_BC, accounting for 50.16% of cases. The prevalence of drug resistance was 5.97% (38/636), with the K103N mutation being the most common. An analysis of transmission networks revealed that 52.2% (272/521) of clusters were associated with CRF07_BC and CRF08_BC. Two novel second-generation CRFs were identified: CRF190_0708, with an estimated time to the most recent common ancestor (tMRCA) of 1998.9, and CRF191_0708, with a more recent tMRCA ranging from 2009.5 to 2011.6. During the five-year follow-up period, viral rebound was observed in 7 patients in the CRF190_0708 group and in 1 patient in the CRF191_0708 group. Drug-resistance mutations (M184V and K103N) were detected in a subset of rebound cases in the CRF190_0708 group. Conclusions: This study identifies two novel HIV-1 recombinants, CRF190_0708 and CRF191_0708, highlighting ongoing viral evolution in Yunnan. Preliminary findings suggest possible clinical differences, warranting further investigation. Continued molecular surveillance is needed. Trial registration: The clinical study was registered at ClinicalTrials.gov under the identifier NCT03852849. The date of registration was March 22, 2019.
- Open Access
- 18 April 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Identification of a novel second-generation HIV-1 circulating recombinant form, CRF182_0708, in Yunnan, China
To report a novel HIV-1 circulating recombinant form (CRF) identified in Yunnan Province, China, through a molecular epidemiological study based on near-fu
- 18 April 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessIdentification of a novel second-generation HIV-1 circulating recombinant form, CRF182_0708, in Yunnan, China
To report a novel HIV-1 circulating recombinant form (CRF) identified in Yunnan Province, China, through a molecular epidemiological study based on near-fu
- Open Access
- 23 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
A rare case report of disseminated Talaromyces marneffei infection presenting as acute pancreatitis in an HIV-1 infected patient
Talaromyces marneffei (TM) is a thermally dimorphic fungus endemic to Southeast Asia and a major opportunistic pathogen in HIV-1/AIDS patients. We report a
- 23 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessA rare case report of disseminated Talaromyces marneffei infection presenting as acute pancreatitis in an HIV-1 infected patient
Talaromyces marneffei (TM) is a thermally dimorphic fungus endemic to Southeast Asia and a major opportunistic pathogen in HIV-1/AIDS patients. We report a
- Open Access
- 26 September 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1624996
Rapid circulation of HIV-1 CRF85_BC in Southwest China: its geographic origins and molecular transmission networks analysis
Background: Until December 2024, China had identified and named 66 new HIV-1 recombinant genotypes. Among them, CRF85-BC is showing a rapidly growing trend in popularity in southwestern China, especially in Sichuan and Yunnan. This genotype was first discovered and reported in Sichuan and is believed to have originated in Yunnan. However, there are relatively few reports on the comprehensive systematic transmission data in Yunnan. This study will further elucidate the accurate evolutionary origin time and epidemic transmission dynamics of CRF85-BC.Methods: We obtained 496 partial pol and 47 near full-length genomic sequences of HIV-1 CRF85_BC from 28,384 individuals with treatment failure in Yunnan, 2009-2023. Bayesian coalescent phylogeny analysis was performed to investigate the origin and timeline of CRF85_BC. A molecular transmission network was constructed using the genetic distance method to evaluate the transmission pattern. Spatial analysis was used to reveal the geographic patterns of phylogenetic clustering rates.Results: The number of CRF85_BC sample cases increased significantly between 2009 and 2023, and showed resistance to reverse transcriptase inhibitors (M184V/I and K103N/S). Bayesian phylogeny of nearly full-length sequences indicated that the emergence time in Yunnan was between January 1989 (95% confidence interval [CI]: 1984.9-1992.8) and February 1992 (95% CI: 1986.1-1996.6). Molecular networks resolved 87 transmission clusters, and the differences in transmission patterns were mainly manifested in the high aggregation rate (63.29%; 95% CI: 55.69%-70.89%) and cluster size (average size: 8.3) in Sichuan, which were higher than those in Yunnan (40.33%; 95% CI: 36.19%-44.47%; average size: 2.5). And all of them were heterosexual people, with a predominance of 77.81% (256/329). Spatiotemporal analysis revealed that Yunnan significantly transmitted to Sichuan, with Zhaotong and Yibin serving as key transmission hubs in both provinces.Conclusions: The CRF85_BC genotype from Yunnan has a growing transmission network, with the potential for further expansion.
- 26 September 2025
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1624996
Open AccessRapid circulation of HIV-1 CRF85_BC in Southwest China: its geographic origins and molecular transmission networks analysis
Background: Until December 2024, China had identified and named 66 new HIV-1 recombinant genotypes. Among them, CRF85-BC is showing a rapidly growing trend in popularity in southwestern China, especially in Sichuan and Yunnan. This genotype was first discovered and reported in Sichuan and is believed to have originated in Yunnan. However, there are relatively few reports on the comprehensive systematic transmission data in Yunnan. This study will further elucidate the accurate evolutionary origin time and epidemic transmission dynamics of CRF85-BC.Methods: We obtained 496 partial pol and 47 near full-length genomic sequences of HIV-1 CRF85_BC from 28,384 individuals with treatment failure in Yunnan, 2009-2023. Bayesian coalescent phylogeny analysis was performed to investigate the origin and timeline of CRF85_BC. A molecular transmission network was constructed using the genetic distance method to evaluate the transmission pattern. Spatial analysis was used to reveal the geographic patterns of phylogenetic clustering rates.Results: The number of CRF85_BC sample cases increased significantly between 2009 and 2023, and showed resistance to reverse transcriptase inhibitors (M184V/I and K103N/S). Bayesian phylogeny of nearly full-length sequences indicated that the emergence time in Yunnan was between January 1989 (95% confidence interval [CI]: 1984.9-1992.8) and February 1992 (95% CI: 1986.1-1996.6). Molecular networks resolved 87 transmission clusters, and the differences in transmission patterns were mainly manifested in the high aggregation rate (63.29%; 95% CI: 55.69%-70.89%) and cluster size (average size: 8.3) in Sichuan, which were higher than those in Yunnan (40.33%; 95% CI: 36.19%-44.47%; average size: 2.5). And all of them were heterosexual people, with a predominance of 77.81% (256/329). Spatiotemporal analysis revealed that Yunnan significantly transmitted to Sichuan, with Zhaotong and Yibin serving as key transmission hubs in both provinces.Conclusions: The CRF85_BC genotype from Yunnan has a growing transmission network, with the potential for further expansion.
- Open Access
- 24 September 2022
- Published by KEAI Publishing in Virologica Sinica
- Vol. 37 (6) , 804-812
Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates
The continuously arising of SARS-CoV-2 variants has been posting a great threat to public health safety globally, from B.1.17 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) to B.1.1.529 (Omicron). The emerging or re-emerging of the SARS-CoV-2 variants of concern is calling for the constant monitoring of their epidemics, pathogenicity and immune escape. In this study, we aimed to characterize replication and pathogenicity of the Alpha and Delta variant strains isolated from patients infected in Laos. The amino acid mutations within the spike fragment of the isolates were determined via sequencing. The more efficient replication of the Alpha and Delta isolates was documented than the prototyped SARS-CoV-2 in Calu-3 and Caco-2 cells, while such features were not observed in Huh-7, Vero E6 and HPA-3 cells. We utilized both animal models of human ACE2 (hACE2) transgenic mice and hamsters to evaluate the pathogenesis of the isolates. The Alpha and Delta can replicate well in multiple organs and cause moderate to severe lung pathology in these animals. In conclusion, the spike protein of the isolated Alpha and Delta variant strains was characterized, and the replication and pathogenicity of the strains in the cells and animal models were also evaluated.
- 24 September 2022
- Published by KEAI Publishing in Virologica Sinica
- Vol. 37 (6) , 804-812
Open AccessCharacteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates
The continuously arising of SARS-CoV-2 variants has been posting a great threat to public health safety globally, from B.1.17 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) to B.1.1.529 (Omicron). The emerging or re-emerging of the SARS-CoV-2 variants of concern is calling for the constant monitoring of their epidemics, pathogenicity and immune escape. In this study, we aimed to characterize replication and pathogenicity of the Alpha and Delta variant strains isolated from patients infected in Laos. The amino acid mutations within the spike fragment of the isolates were determined via sequencing. The more efficient replication of the Alpha and Delta isolates was documented than the prototyped SARS-CoV-2 in Calu-3 and Caco-2 cells, while such features were not observed in Huh-7, Vero E6 and HPA-3 cells. We utilized both animal models of human ACE2 (hACE2) transgenic mice and hamsters to evaluate the pathogenesis of the isolates. The Alpha and Delta can replicate well in multiple organs and cause moderate to severe lung pathology in these animals. In conclusion, the spike protein of the isolated Alpha and Delta variant strains was characterized, and the replication and pathogenicity of the strains in the cells and animal models were also evaluated.
- 24 March 2022
- Published by Elsevier in Journal of Infection
- Vol. 84 (6) , e112-e115
Characterization of a Newly Emerging HIV-1 Second-Generation Recombinant Form (CRF125_0107) Among Heterosexuals in Yunnan, China
- 24 March 2022
- Published by Elsevier in Journal of Infection
- Vol. 84 (6) , e112-e115
Characterization of a Newly Emerging HIV-1 Second-Generation Recombinant Form (CRF125_0107) Among Heterosexuals in Yunnan, China
- 1 August 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (2) , 237-279
Genetic characteristics of a New HIV-1 subtype B/C intersubtype circulating recombinant form (CRF118_BC) identified in Yunnan, China
- 1 August 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (2) , 237-279
Genetic characteristics of a New HIV-1 subtype B/C intersubtype circulating recombinant form (CRF118_BC) identified in Yunnan, China
- 1 March 2021
- Published by Elsevier in Journal of Infection
- Vol. 82 (3) , e8-e10
A newly emerging HIV-1 circulating recombinant form (CRF110_BC) comprising subtype B and C among intravenous drug users in Yunnan, China
- 1 March 2021
- Published by Elsevier in Journal of Infection
- Vol. 82 (3) , e8-e10
A newly emerging HIV-1 circulating recombinant form (CRF110_BC) comprising subtype B and C among intravenous drug users in Yunnan, China
- Open Access
- 1 January 2021
- Published by Zoological Research in Zoological Research
- Vol. 42 (2) , 161-169
Lower respiratory tract samples are reliable for severe acute respiratory syndrome coronavirus 2 nucleic acid diagnosis and animal model study
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continue to impact countries worldwide. At present, inadequate diagnosis and unreliable evaluation systems hinder the implementation and development of effective prevention and treatment strategies. Here, we conducted a horizontal and longitudinal study comparing the detection rates of SARS-CoV-2 nucleic acid in different types of samples collected from COVID-19 patients and SARS-CoV-2-infected monkeys. We also detected anti-SARS-CoV-2 antibodies in the above clinical and animal model samples to identify a reliable approach for the accurate diagnosis of SARS-CoV-2 infection. Results showed that, regardless of clinical symptoms, the highest detection levels of viral nucleic acid were found in sputum and tracheal brush samples, resulting in a high and stable diagnosis rate. Anti-SARS-CoV-2 immunoglobulin M (IgM) and G (IgG) antibodies were not detected in 6.90% of COVID-19 patients. Furthermore, integration of nucleic acid detection results from the various sample types did not improve the diagnosis rate. Moreover, dynamic changes in SARS-CoV-2 viral load were more obvious in sputum and tracheal brushes than in nasal and throat swabs. Thus, SARS-CoV-2 nucleic acid detection in sputum and tracheal brushes was the least affected by infection route, disease progression, and individual differences. Therefore, SARS-CoV-2 nucleic acid detection using lower respiratory tract samples alone is reliable for COVID-19 diagnosis and study.
- 1 January 2021
- Published by Zoological Research in Zoological Research
- Vol. 42 (2) , 161-169
Open AccessLower respiratory tract samples are reliable for severe acute respiratory syndrome coronavirus 2 nucleic acid diagnosis and animal model study
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continue to impact countries worldwide. At present, inadequate diagnosis and unreliable evaluation systems hinder the implementation and development of effective prevention and treatment strategies. Here, we conducted a horizontal and longitudinal study comparing the detection rates of SARS-CoV-2 nucleic acid in different types of samples collected from COVID-19 patients and SARS-CoV-2-infected monkeys. We also detected anti-SARS-CoV-2 antibodies in the above clinical and animal model samples to identify a reliable approach for the accurate diagnosis of SARS-CoV-2 infection. Results showed that, regardless of clinical symptoms, the highest detection levels of viral nucleic acid were found in sputum and tracheal brush samples, resulting in a high and stable diagnosis rate. Anti-SARS-CoV-2 immunoglobulin M (IgM) and G (IgG) antibodies were not detected in 6.90% of COVID-19 patients. Furthermore, integration of nucleic acid detection results from the various sample types did not improve the diagnosis rate. Moreover, dynamic changes in SARS-CoV-2 viral load were more obvious in sputum and tracheal brushes than in nasal and throat swabs. Thus, SARS-CoV-2 nucleic acid detection in sputum and tracheal brushes was the least affected by infection route, disease progression, and individual differences. Therefore, SARS-CoV-2 nucleic acid detection using lower respiratory tract samples alone is reliable for COVID-19 diagnosis and study.